Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9986)
All Articles published online
|
Publishing Process of This Article
|
May 27, 2019 (publication date) through Nov 3, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Xie Q, Xuan JW, Tang H, Ye XG, Xu P, Lee IH, Hu SL. Hepatitis C virus cure with direct acting antivirals: Clinical, economic, societal and patient value for China. World J Hepatol 2019; 11(5): 421-441 [PMID: 31183003 DOI: 10.4254/wjh.v11.i5.421] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v11/i5/421.htm |
| Number | Citing Articles |
| 1 |
Malik Sallam, Roaa Khalil. Contemporary Insights into Hepatitis C Virus: A Comprehensive Review. Microorganisms 2024; 12(6): 1035 doi: 10.3390/microorganisms12061035
|
| 2 |
Rong Chen, Jun Chen, Qi Tang, Zhihao Meng, Ling Luo, Wei Zhang, Aihua Deng, Lukun Zhang, Jiangrong Wang, Tangkai Qi, Renfang Zhang, Yinzhong Shen, Li Liu, Corky Steinhart, Hongzhou Lu. Use of comedications and potential drug-drug interactions in people living with HIV in China. Journal of Infection and Chemotherapy 2020; 26(7): 722 doi: 10.1016/j.jiac.2020.04.003
|
| 3 |
Ahmed Saqer Alotaibi, Nour Shamas, Umair Uddin Ansari, Faisal M. Sanai, Ali Alshahrani, Ahmed Ibrahim Fathelrahman, Mohammed Ali Aseeri. Impact of Drug Use Policy on the Appropriate Use of Direct Acting Antiviral Agents for Hepatitis C in Saudi Arabia. Journal of Pharmacy and Bioallied Sciences 2021; 13(3): 317 doi: 10.4103/jpbs.jpbs_166_21
|
| 4 |
Mohammed El Behery, AhmedI. Elghwab, Ashraf A. Tabll, Elsherbiny H. Elsayed, Mohamed A. Abdelrazek. Serum collagen IV as a predictor for response to direct-acting antivirals hepatitis C therapy. Journal of Immunoassay and Immunochemistry 2024; : 1 doi: 10.1080/15321819.2024.2415882
|
| 5 |
V.I. Trykhlib. Хронический вирусный гепатит С. Эффективность противовирусной терапии. Данные методических рекомендаций ВОЗ (обзор литературы). ACTUAL INFECTOLOGY 2021; 8(1): 1 doi: 10.22141/2312-413x.8.1.2020.196165
|
| 6 |
Yuting He, Yichong Wang, Xuefang Chen, Hao Huang, Jiankai Deng, Peisong Chen, Huang Bin. Performance evaluation of the DAAN HCV assay for quantification of hepatitis C virus RNA and its comparison with COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test, v2.0. Journal of Clinical Laboratory Analysis 2020; 34(7) doi: 10.1002/jcla.23280
|
| 7 |
Liangying Gan, Dongyu Wang, Brian Bieber, Keith McCullough, Michel Jadoul, Ronald L. Pisoni, Fanfan Hou, Xinling Liang, Zhaohui Ni, Xiaonong Chen, Yuqing Chen, Li Zuo. Hepatitis C Prevalence, Incidence, and Treatment in Chinese Hemodialysis Patients: Results From the Dialysis Outcomes and Practice Patterns Study-China (2019–21). Frontiers in Medicine 2022; 9 doi: 10.3389/fmed.2022.910840
|
| 8 |
Maan T. Khayat, Abdelsattar M. Omar, Mahmoud A. Elfaky, Yosra A. Muhammad, Elaf A. Felemban, Khalid M. El-Say, Moustafa E. El-Araby, Jin Xie. Reexamining Povarov Reaction’s Scope and Limitation in the Generation of HCV-NS4A Peptidomimetics. Heteroatom Chemistry 2022; 2022: 1 doi: 10.1155/2022/8181543
|
| 9 |
Jinyu Liu, Yu Zhang, Bin Wu, Sen Wang, David Bin-Chia Wu, Ruxu You. Cost-Effectiveness of Testing for NS5A Resistance to Optimize Treatment of Elbasvir/Grazoprevir for Chronic Hepatitis C in China. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.717504
|
| 10 |
Halinuer Shadekejiang, Jiefu Zhu, Xiongfei Wu. Transplant of Kidneys From Hepatitis C Virus-Positive Donors To Hepatitis C Virus-Negative Recipients: A Retrospective Study and Systematic Review. Experimental and Clinical Transplantation 2022; 20(12): 1076 doi: 10.6002/ect.2022.0315
|
| 11 |
Mingyang Li, Hui Zhuang, Lai Wei. How would China achieve WHO’s target of eliminating HCV by 2030?. Expert Review of Anti-infective Therapy 2019; 17(10): 763 doi: 10.1080/14787210.2019.1675509
|